Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027651 (tumor)
 685,946 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The reaction of leucocyte migration inhibition (RLMI), using antigens of autochthonous and allogenic tumors, was utilized to examine 21 patients with renal cancer and in 37 control patients. The antigens of renal cancer (AG RC) would suppress specifically leucocyte migration in all patients with cancer of the kidney, as compared with the migration without antigens or in the presence of normal tissue antigens of the tumor involved kidney. In 5 of 37 cases AG RC as well as those of normal renal tissue inhibited leucocyte migration in patients with urolithiasis and pyelonephritis. Autologous blood plasma in patients with renal cancer would contribute to inhibition of leucocyte migration by cancer antigens. There are some common specific antigens in renal cancer, recognized by lymphocytes from different patients with the tumor in question. RLMI may be used to establish the immune diagnosis of cancer of the kidney.
 ...
PMID:[Suppression of leukocyte migration by autologous and allogeneic tumor extracts in kidney cancer patients]. 8 31

A proportion of cancers in endocrine target tissues can show the presence of specific receptors for either steroid or polypetide hormones. Manipulation of the controlling hormones does not guarantee regression. A third of cancers in endocrine target organs (breast, uterine endometrium, and prostate) show a 50% reduction in size of lesions after hormonal therapy. If regression resulting from an aggressive form of therapy lasts a short while and the tumor reactivates by the time the unpleasant effects of the therapy wear off, the treatment is not palliative. Endocrine therapy in prostatic cancer is palliative but there is no evidence that is increases survival. 11 different progestational agents in endometrial cancer therapy in the past 25 years resulted in a 30-35% response. Response must be maintained by continual treatment and may last from 12 months to 7-8 years. In breast cancer, tumors with a significant level of estrogen receptor (ER+) have about a 60% chance of regression vs. tumors without estrogen receptors (ER-), 10%. Advanced cancers of the thyroid of the papillary or follicular type regress when the patient is treated by thyroxine, .3 mg daily. Leukemia and lymphoma are frequently treated, with varying degrees of success with corticosteroid therapy, which may also predispose the patient to intercurrent infection. Renal cancer has been often treated by medroxyprogesterone acetate or testosterone propionate, with little success.
 ...
PMID:Endocrine therapy in cancer. 8 86

Critical examination of the results of surgical treatment and new surgical techniques have produced changes in the operative treatment of hypernephroid kidney cancer and nephroblastoma. The limits to operative treatment are, first, the local extension and infiltration of the tumor and, second, the grade and degree of metastases. Surgical removal of the hypernephroma seems to have a positive effect on metastasis regression only in the case of bone metastases. Nephrectomy is indicated only in cases with solitary metastases which can be removed at a second operation. The possibility of arterial embolization in renal hemorrhage in inoperable patients is demonstrated. Current aspects of the operative treatment of nephroblastoma are discussed.
 ...
PMID:[The problem of surgical therapy of malignant kidney tumors]. 19 6

Abdominal pansonography was performed in 34 patients after solid renal tumors were diagnosed. Included were evaluation of the inferior vena cava (IVC), the liver, and the retroperitoneal area. Additional findings including hepatic metastases, IVC extension of tumor, and retroperitoneal nodal masses were discovered in 14 patients. The role of pansonography as a noninvasive adjunctive diagnostic tool for more complete staging and treatment planning of renal cancer is discussed.
 ...
PMID:Abdominal pansonography in the evaluation of renal cancer. 22 95

Histological examination of the gingivovestibular lesion in the first case with known kidney cancer, confirmed the metastatic nature of the buccal tumor and its origin. The second case raised the problem of the diagnosis of a labial swelling occurring during widespread metastases from breast cancer. The third case was more complex as the palatine lesion was seen initially, and metastatic seeding extremely rapid. This led to the hypothesis only, that bronchial cancer was the primary lesion.
 ...
PMID:[Buccal metastases from soft-tissue cancers. A report on 3 cases (author's transl)]. 29 Nov 14

The cellular immune response has been reported to be impaired in patients with renal cancer and to be increased by removal of the tumor bulk. T lymphocyte levels in the vein of the neoplastic kidney were investigated in 4 patients to assess the presence of a T lymphocyte inhibiting factor produced by the tumor. T lymphocyte levels resulted in significantly decreased tumorous venous blood, whether compared to arterial, contralateral or peripheral blood. A similar result was not found in 10 control patients. Some hypotheses on the nature of this T lymphocyte inhibition are discussed.
 ...
PMID:T lymphocytes inhibiting factors in renal cancer: evaluation of differences between arterial and renal venous blood levels of E rosette forming cells. 31 Apr 75

Patients with metastatic renal cell cancer have an overall 5-year survival rate of only 28% to 40% in spite of aggressive surgical treatment. A prospective randomized study conducted by the Eastern Cooperative Oncology Group used methyl--CCNU (meCCNU), vinblastine, and meCCNU-medroxyprogesterone acetate (MPA) to treat 165 patients with advanced renal cancer. The antitumor activity of the single-agent and/or combination therapy is analyzed. Patients were classified (as to grade of anaplasia of tumor; age; performance status; primary site of metastatic disease; and previous treatment with a progestational agent) and randomly assigned to various treatment protocols as described. Crossover randomization to one of alternate single-agent or combination regimens was carried out after failure with initial therapy. 2 meCCNU regimens were associated with severe hematologic toxicity, vinblastine regimens with neurotoxicity. All regimens except the vinblastine-MPA resulted in substantial vomiting. Response rate is low (11%) with each regimen. There were no statistically significant differences in treatment variables or factors among the various regimens. Patients capable of normal activity had a significantly higher response rate and longer survival period than nonambulatory or poor performance status patients. A relatively long symptom-free interval from primary tumor to metastatic disease was also associated with better survival rate. More than 50% of patients exhibited disease progression with 3 months of initiating the regimens.
 ...
PMID:Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer. 35 71

Lipotropin (LPH) has been evaluated as a potential tumor marker using a sensitive beta melanocyte-stimulating hormone (beta MSH) radioimmunoassay. All 79 acetic acid extracts of carcinomas of lung, colon, stomach, esophagus and breast contained LPH in concentrations greater than blood; 61 of 79 extracts contained LPH in larger amounts than control tissues from patients without cancer. In a blind prospective study, plasma LPH was quantified in 107 patients admitted for work-up because of an abnormality on a chest roentgenogram. Thirty-one of 33 patients subsequently diagnosed as having benign lesions had plasma LPH within the 95 per cent confidence limits of normal subjects whereas 28 (36 per cent) of the 74 patients subsequently diagnosed histologically as having primary lung carcinoma had elevated levels. In control studies, 13 of 100 patients with chronic obstructive pulmonary disease had elevated plasma LPH levels; three of the 13 with elevated levels and four with normal levels have been diagnosed, during the two years of follow-up, as having lung carcinoma. In control studies of 23 patients with granulomatous lung disease, 22 had normal levels of LPH. In those with carcinoma of the colon elevated plasma LPH levels were observed in two of 21 untreated patients and in 11 of 61 patients receiving noncurative chemotherapy. Elevated plasma LPH levels were also observed in 10 of 59 patients with breast cancer, eight of 28 with pancreatic cancer, eight of 22 with gastric or esophageal cancer, six of 16 with renal cancer, four of eight with prostatic cancer, one of seven with cervical cancer and one of six with ovarian cancer. We conclude, an elevated LPH level is frequently observed in blood and tumor tissue from patients with various types of carcinoma.
 ...
PMID:Ectopic production of lipotropin by cancer. 43 67

Sera from 28 patients with renal cancer were tested for reactivity with surface antigens of cultured autologous renal cancer cells. Four serological assays were used to survey sera for autologous antibody. Immune adherence, protein A, and C3-mixed hemadsorption assays detected reactivity in a high percentage of patients (80-100%), whereas mixed hemadsorption assays were negative with sera from all but one patient. Reactive sera from six patients were analyzed by absorption tests with autologous, allogeneic, and restricted to autologous renal cancer cells; class 2 antigens, present on certain allogeneic renal and nonrenal cancer cells; and class 3 antigens, found on a wide variety of normal and malignant cell types. The sera of one patient detected class 1, 2, and 3 antigens, the sera of three patients detected class 2 antigens, and the sera of two patients detected class 3 antigens. This analysis of renal cancer, with the recognition of three classes of surface antigens recognized by autologous sera, resembles the results of autologous typing of three other human malignancies: malignant melanoma, acute leukemia, and astrocytoma. Evidence provided by autologous typing of these cancers indicates that class 1 and class 2 antigens are tumor-restricted and that under certain circumstances these antigens are immunogenic for the autologous host.
 ...
PMID:Cell surface antigens of human renal cancer defined by autologous typing. 47 62

Dimethylnitrosamine (DMN) induced a significant incidence (45.5%) of kidney epithelial tumors in adult male Balb/C mice. The proportion of mice with renal tumors orchiectomized after DMN injection was reduced to 25.6%; whereas the proportion of tumor bearing animals at other sites, such as lung, liver, and lymphatic tissue, increased compared to intact DMN treated animals and controls. This experiment confirms other studies in rats and mice showing that androgens play a role in initiation and progression of nitrosamine induced renal cancer, paralleling the finding of increased male susceptibility in human renal cancer.
 ...
PMID:Decreased incidence of renal tumors in DMN treated Balb/C mice after orchiectomy. 59 45


1 2 3 4 5 6 7 8 9 10 Next >>